Sea Crest Wealth Management, LLC Verastem, Inc. Transaction History

Sea Crest Wealth Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 13, 2020	SELL	$1.26 - $3.38 $14,668 - $39,349	-11,642 Closed	0 $0
Q4 2019 Jan 22, 2020	SELL	$0.86 - $1.44 $11,219 - $18,786	-13,046 Reduced 52.84%	11,642 $16,000
Q3 2019 Oct 15, 2019	SELL	$1.21 - $1.59 $10,945 - $14,383	-9,046 Reduced 26.82%	24,688 $30,000
Q2 2019 Jul 19, 2019	SELL	$1.25 - $3.14 $23,151 - $58,155	-18,521 Reduced 35.44%	33,734 $51,000
Q1 2019 May 10, 2019	SELL	$2.79 - $4.09 $53,827 - $78,908	-19,293 Reduced 26.97%	52,255 $155,000
Q4 2018 Feb 13, 2019	BUY	$3.23 - $7.01 $70,368 - $152,719	21,786 Added 43.78%	71,548 $240,000
Q3 2018 Nov 14, 2018	BUY	$6.86 - $9.97 $86,833 - $126,200	12,658 Added 34.11%	49,762 $361,000
Q2 2018 Aug 03, 2018	BUY	$2.88 - $8.67 $56,594 - $170,374	19,651 Added 112.59%	37,104 $255,000
Q1 2018 Apr 20, 2018	SELL	$2.92 - $3.81 $52,235 - $68,157	-17,889 Reduced 50.62%	17,453 $52,000
Q4 2017 Feb 02, 2018	BUY	$2.99 - $4.85 $105,672 - $171,408	35,342	35,342 $108,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.2B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Sea Crest Wealth Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sea Crest Wealth Management, LLC with notifications on news.